知镜 Cognispect · 医学文献与研究工作台

Post-transplant lineage transformation to blastic plasmacytoid dendritic cell neoplasm in advanced systemic mastocytosis with associated CMML: a case report.

Khaled O, Woodman A, Farjami C, Goldstein Z, Tam EL, Woan K, Chaudhary P, Ali A, Siddiqi IS, Yaghmour G.
Current research in translational medicine · 2026-10-24 · PMID 42998573

文献摘要

Advanced systemic mastocytosis with associated hematologic neoplasm (SM-AHN) is a rare, genomically unstable disorder with a high risk of clonal evolution. We report a 74-year-old man with SM-AHN (chronic myelomonocytic leukemia subtype) harboring KRAS, RUNX1, SRSF2, and TET2 mutations who was treated with avapritinib, hypomethylating therapy, and matched-unrelated donor allogeneic stem cell transplantation. Nine months post-transplant, he developed a violaceous cutaneous lesion. Histopathology and immunophenotyping confirmed blastic plasmacytoid dendritic cell neoplasm (BPDCN). Next-generation sequencing of the lesion revealed shared SRSF2 and TET2 mutations with the antecedent CMML clone and acquisition of a novel GNB1 mutation, supporting clonal evolution under treatment-related selective pressure and post-transplant immune modulation. Diagnostic distinction from mastocytosis relapse, leukemia cutis, and graft-versus-host disease requires integrated morphologic, immunophenotypic, and molecular evaluation. Treatment with CD123-directed tagraxofusp was complicated by severe capillary leak syndrome, and the patient passed away following re-challenge, underscoring the substantial risk this therapy carries in heavily pretreated, post-transplant patients. BPDCN may represent a late manifestation of clonal progression after allo-HSCT, emphasizing the importance of longitudinal molecular monitoring and vigilance for new cutaneous lesions in post-transplant patients with SM-AHN.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。